CD28


Also found in: Wikipedia.

CD28

a type I transmembrane protein present on most CD4 T cells, many CD8 T cells, and most plasma cells that enhances the transcription and stability of IL-2 messenger RNA.
References in periodicals archive ?
Tasuku Honjo, "for their discovery of cancer therapy by inhibition of negative immune regulation." Among his most notable discoveries are the determination of the T-cell receptor structure and that CD28 is the major costimulatory molecule that allows full activation of naive T-cells and prevents anergy in T-cell clones.
Effector cells: CD62L, CD44, CD45RA, CD45RO, CD27, CD28, CD69, Costimulatory molecules CTLA4, ICOS, FAS, PD-1, CD25, CD127, - chemokine receptors CCR7, CCR4, CXCR3, CXCR4, CXCR5, CCR6, CX3CR1, - apoptosis / living dead differentiation annexin, live dye z.
The second, ALPN-202 for cancer, is a dual PD-L1/CTLA-4 antagonist and PD-L1-dependent CD28 costimulator intended to combine checkpoint inhibition with T cell costimulation an approach currently absent from approved checkpoint therapies.
The CTLA-4 has a higher binding affinity for CD28 and CD86 compared to CD28.
Cytotoxic T lymphocyte antigen-4 reverses the activity of the T cell co-stimulator receptor called CD28. CD28 and CTLA-4 share similar ligands called CD80 (B7.1) and CD86 (B7.2).
Interestingly, the CD28 expression was lower in [CD8.sup.+] T cells from chronic apical periodontitis.
Su entrega y su pasion por la ciencia a lo largo de mas de 30 anos, le permitieron responder a preguntas fundamentales sobre el funcionamiento y la regulacion de estas celulas: fue el primero en aislar el receptor del antigeno TCR, el receptor de activacion CD28 y el receptor de inhibicion CTLA-4.
Reltecimod (AB103) is a rationally designed peptide that binds to the CD28 co-stimulatory receptor and restores the host's appropriate immune response to severe infections.
Furthermore, recent data showed that CD28 is a major target for PD-1 inhibition both in vitro and in vivo (31,32).
The costimulatory signal is produced by cooperation between CD28 attached to T cell and B7 molecules on antigen-presenting cells (1-3).
In 2006, the phase 1 clinical study was conducted for a CD28 superagonist antibody TGN1412 in six male human volunteers.
Studies in twins have recommended that the genetic background has 79% contribution in the development of GD.6 The human cluster of differentiation 40 (CD40) gene performs a primary function in activation of B-cell and antibody production.7 CD40 C/T-1 is an efficient single-nucleotide polymorphism (SNP) situated at position1 in the promoter area and it is reported to be associated with GD as it disturbs the CD40 translation levels.8 On the other hand, CD28 speeds up T-cell activities that are important for antigen-specific immune responses.9 The current study was planned to find out the genotype and allelic frequency at C/T-I3 + 17 SNP in CD28 and CD40 Cytadine/Thymadine deoxy ribonucleotide C/T-1 SNP inCD40 in clinically diagnosed GD patients and in their age-match controls.